Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Fujirebio

Tracked across 4 events · 75 articles · First seen Apr 14, 2026 · Last active Aug 24, 2026

Sentiment
26
Attention
4
Events
4
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 60
Business
Impact: Fujirebio is a key player in the CLIA market, contributing significantly to market advancements with diverse product offerings and strategies.
Jun 05, 2026 · 6 articles
1 40
Business
Impact: Formed partnership with Agappe to develop diagnostics.
Jul 08, 2026 · 6 articles
4 25
Tech
Impact: Manufactures the FDA-cleared Lumipulse G pTau217 test; potential commercial beneficiary.
Jul 15, 2026 · 56 articles
4 -20
Regulatory
Impact: Fujirebio's Lumipulse was the first FDA-cleared Alzheimer's blood test, but now faces increased competition from the Roche/Lilly test.
Aug 24, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Fujirebio live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.